Introduction 38
Mycobacterium abscessus (or M. abscessus subsp. abscessus), M. massiliense (or M. 39 abscessus subsp. massiliense), and M. bolletii (or M. abscessus subsp. bolletii) comprise the M. 40 abscessus complex (MABC) (1) . These rapidly-growing nontuberculous mycobacteria, 41 ubiquitous in the environment, are opportunistic human pathogens associated with a wide range 42 of maladies, from localized skin lesions to systemic disease. Individuals with cystic fibrosis and 43 other forms of bronchiectasis are especially vulnerable to MABC pulmonary disease, an 44
infection that is notoriously difficult to eradicate due in large part to MABC's broad, intrinsic 45 resistance to most antibiotics, including many anti-mycobacterial drugs (2-4). The paucity of 46 effective treatment regimens has recently gained attention as the prevalence of MABC 47 pulmonary disease is apparently increasing (5-7), justly highlighting the need for additional 48 treatment options. 49
Like several other pathogenic and nonpathogenic mycobacteria, MABC organisms possess a 51 constitutively expressed, broad-spectrum β-lactamase, BlaMab, which contributes to the intrinsic 52 resistance of MABC to most β-lactam antibiotics (8) (9) (10) (11) (12) . Several studies have indicated that 53
BlaMab is not significantly inhibited by β-lactam-based β-lactamase inhibitors, namely 54 clavulanate, tazobactam, and sulbactam (9, (13) (14) (15) . In contrast, the non-β-lactam-based 55 β-lactamase diazabicyclooctane (DBO) inhibitor avibactam does inhibit BlaMab, thereby reducing 56 the minimum inhibitory concentration (MIC) of many β-lactams for MABC, especially 57 carbapenems and cephalosporins, to clinically achievable concentrations (16) (17) (18) (19) (20) . Avibactam is 58 marketed solely in combination with the cephalosporin ceftazidime (trade name AVYCAZ ® in the 59 United States). However, ceftazidime has little or no demonstrable activity against MABC, even 60 in combination with avibactam and against M. abscessus strains in which the gene encoding 61
BlaMab has been entirely deleted (8, 9, 18) . Thus, the current requirement to co-administer 62 ceftazidime in order to potentiate the activity of other more effective β-lactams with avibactam Page 4 complicates this treatment strategy for MABC infections, as ceftazidime might only incur risk of 64 adverse effects without perceived benefit. 65
Relebactam and vaborbactam are two newer non-β-lactam-based β-lactamase inhibitors 67 developed for use with the carbapenems imipenem and meropenem, respectively (21). 68
Whereas relebactam is a DBO β-lactamase inhibitor structurally related to avibactam, 69 vaborbactam is a novel boronic acid-based inhibitor. While neither of these β-lactamase 70
inhibitors are expected to be clinically available as sole formulations, both of the paired 71 carbapenems have activity against MABC. Imipenem alone has good activity and is currently 72 recommended as part of first-line treatments for MABC pulmonary disease (2, 3). Activity of 73 meropenem, while comparatively less than imipenem when used alone, is increased 74 comparable to that of imipenem in the presence of avibactam (8, 16, 18 could not be determined until nearly 5 days of incubation ( Fig. S1A) . Such a long incubation 94 period can be problematic when evaluating the activity of some β-lactams due to their innate 95 instability in aqueous media, independent of the presence of β-lactamase enzymes (8, (23) (24) (25) , representing the four major sub-classes of β-lactams (carbapenems, cephalosporins, 105 monobactams, and penicillins) were determined in the presence and absence of relebactam or 106 vaborbactam at 4 µg/ml ( Table 1) . Neither of these β-lactamase inhibitors exhibited 107 antimicrobial activity on their own. The MICs of relebactam alone and vaborbactam alone were 108 both >256 µg/ml, and neither drug inhibited bacterial growth in a disk diffusion assay ( Fig. S2) . 109
As expected, without co-exposure to a β-lactamase inhibitor, the strain was able to grow in 110 relatively high concentrations of all β-lactams tested, with imipenem having the lowest MIC at 111 8 µg/ml. Overall, the MICs of penicillins and the monobactam aztreonam were not affected by 112 either β-lactamase inhibitor, although the MIC of amoxicillin did shift from >256 µg/ml to 32 113 µg/ml in the presence of relebactam. In contrast, all carbapenems and more than half of the 114 cephalosporins tested exhibited decreased MICs in the presence of either relebactam or Page 6
vaborbactam. The magnitude of the MIC shift associated with each β-lactamase inhibitor was 116 similar for most of these β-lactams, but for two of the carbapenems (tebipenem and ertapenem) 117 and three of the cephalosporins (cefdinir, cefuroxime, and ceftaroline) the MICs associated with 118 relebactam were one dilution lower than that associated with vaborbactam. Similar activity was 119 also observed in a disk diffusion assay ( Fig. S2) . 120 121
Activity of β-lactams with relebactam or vaborbactam against MABC clinical isolates 122
The promising antimicrobial activity of the carbapenems and select cephalosporins, namely 123 cefdinir, cefpodoxime, cefuroxime, cefepime, cefotaxime, cefoxitin, ceftaroline, and ceftriaxone, 124 in combination with either relebactam or vaborbactam against the ATCC 19977 strain prompted 125 us to evaluate the activity of these combinations against a collection of 28 MABC clinical 126 isolates with MDR phenotypes (16). The MICs of the carbapenems and cephalosporins against 127 each clinical isolate are presented in Tables S1 and S2, respectively. With the exception of 128 cefoxitin, the MICs of each β-lactam decreased in the presence of either β-lactamase inhibitor 129 ( Table 2) . As observed with the ATCC 19977 strain, both β-lactamase inhibitors were mostly 130 associated with MIC shifts of similar magnitude, although the MIC50, MIC90, and MIC range limits 131 associated with relebactam were one or two dilutions lower than those associated with 132 vaborbactam for tebipenem, biapenem, and meropenem. For tebipenem, 25/28 (89%) isolates 133 has lower MIC values with relebactam compared to vaborbactam, and for biapenem and 134 meropenem, 14/28 (50%) and 10/28 (36%) of the isolates, respectively, had lower MICs with 135 relebactam compared to vaborbactam. For the carbapenems, the most striking shifts in MIC 136 distribution were observed with tebipenem and ertapenem ( Fig. 1A,B ), while the lowest MIC 137 values were obtained with imipenem, meropenem, biapenem, and doripenem ( Fig. 1C-F) . The 138 MIC50 value for each of these carbapenems was 4-8 µg/ml in the presence of either 139 β-lactamase inhibitor, suggesting that they have similar intrinsic activity in the absence of 140 hydrolysis by BlaMab. For the cephalosporins, the largest shifts in MIC distribution associated Page 7 with the β-lactamase inhibitors were observed for ceftaroline, ceftriaxone, and cefuroxime ( Fig.  142 2A-C), while the shifts were comparatively smaller for cefotaxime and cefepime ( Fig. 2D,E) . The 143 MIC distribution of cefoxitin was not affected by the presence of either relebactam or 144 vaborbactam (Fig. 2F) . The lowest MICs in association with a β-lactamase inhibitor were 145 observed with cefuroxime, cefepime, cefdinir, and ceftaroline. 146
147
For a selection of β-lactams, MIC values with and without the β-lactamase inhibitors were also 148 determined in CAMHB. For the ATCC 19977 strain, the MICs were determined after 3 days of 149 incubation, while the MICs for clinical isolates could not be determined before day 4 or 5 of 150 incubation ( Table S3 ). For three of the clinical isolates (strains 2N, 11N, and JHHKB), adequate 151 growth for determining MIC values did not occur within 5 days. With the exception of imipenem 152 and cefdinir, the MIC50 values of the tested β-lactams were higher, both the presence and 153 absence of relebactam or vaborbactam (Table S4) , relative to the MIC50 values determined in 154
Middlebrook 7H9 liquid medium ( Table 2) . The MIC values the ATCC 19977 strain also tended 155 to be higher in CAMHB (Table S3) . Another interesting finding of our study is that the MICs of the carbapenems and 235 cephalosporins, alone and in combination with relebactam or vaborbactam, against the ATCC 236 19977 strain were often similar to MICs against the MABC clinical isolates (Tables S1, S2). For 237
all of the 15 drugs tested, the MIC for the ATCC 19977 strain fell within one dilution of the MIC50 238 for the clinical isolates (Tables 1, 2) . Thus, the MDR clinical isolates, which were isolated from 239 patients with cystic fibrosis and therefore likely previously exposed to β-lactam drugs, were still 240 largely vulnerable to those cephalosporins and carbapenems with activity against MABC 241 transpeptidase targets. These findings also suggest that the widely used and well-characterized 242 M. abscessus strain ATCC 19977 (29) is a suitable model strain for the evaluation of β-lactam 243 activity, with or without β-lactamase inhibitors, and therefore can serve as a valuable tool for studying the molecular mechanisms of intrinsic susceptibility and resistance of MABC to 245 β-lactams. 246 247 CLSI guidelines state that broth MIC testing of rapidly-growing mycobacteria, including MABC, 248 should be performed using CAMHB (22), but we found that our MABC clinical isolates grew 249 poorly in this medium, allowing MIC reading to be done after 4, 5, or even 6 days of incubation 250 ( Fig. S1 , Table S3 ). Due to concerns that the inherent instability of β-lactams may lead to 251 artificially high MIC values after such prolonged incubation periods (8, 23-28), we relied 252 primarily on Middlebrook 7H9 liquid medium for the broth MIC assays in this study. However, we 253 also evaluated a selection of carbapenems and cephalosporins in CAMHB, and found that, in 254 general, the MICs were indeed higher in CAMHB compared to Middlebrook 7H9 medium 255 (Tables 2, S4 ). We also observed that MICs against strain ATCC 19977, which grew 256 equivalently in either type of media, tended to be higher in CAMHB, indicating that media-257 specific factors may influence the anti-MABC activity of β-lactams. There are other reports of 258 higher β-lactam MICs against strain ATCC 19977 in CAMHB compared to in Middlebrook 7H9 259 liquid medium (16, 18, 19) . As CAMHB is recommended for use in clinical microbiology 260 laboratories for antimicrobial susceptibility testing of MABC isolates from patient samples, it will 261 be important to understand the basis of these apparent media-dependent discrepancies in 262 MABC susceptibility to β-lactams. Ultimately, the imperative is to understand which MICs in any 263
given medium correlate with in vivo activity. Preclinical animal models suitable for testing the 264 antimicrobial activity of β-lactams against MABC would be useful to address this issue, but the 265 absence of a well-qualified animal model is currently a critical missing link in our ability to 266 translate in vitro activity to clinical utility. 267
268
In conclusion, the data presented in this study demonstrate that the β-lactamase inhibitors 269 vaborbactam and relebactam markedly improve the anti-MABC activity of many carbapenems Page 12 and cephalosporins and should improve the clinical utility of some of these β-lactams. Each of 271 these β-lactamase inhibitors is currently formulated with a carbapenem: vaborbactam with 272 meropenem and relebactam with imipenem, and our data suggest that these fixed combinations 273 will be more useful for the treatment of MABC disease than either carbapenem alone, especially 274 in the case of meropenem. Moreover, the combinations of meropenem/vaborbactam and, if it is 275 approved in the future, imipenem/relebactam, would make it unnecessary to combine the 276 carbapenems with the marketed ceftazidime/avibactam combination in order to gain effective β-277 lactamase inhibition. Hence, they may quickly become the preferred β-lactams for MABC lung 278 disease. Finally, given the burgeoning interest in combining β-lactams from different classes to 279 obtain synergistic effects against mycobacteria, our findings suggest several cephalosporins 280 whose potency is enhanced by BlaMab inhibition that are worthy of combining with a fixed 281 carbapenem/β-lactamase inhibitor combination. Cefuroxime may be of particular interest given 282 Growth curves. MABC strains were grown from frozen stock in growth medium, shaking, at 325 37°C, until the cultures reached log-phase growth (optical density at 600 nm [OD600] between 326 0.4 to 0.7). The bacterial suspensions were then adjusted to an OD600 of 0.01 using 7H9 and 327 CAMHB MIC assay media, in a total volume of 15 mL in 50-mL polystyrene tubes. The cultures 328 were incubated without agitation at 30°C, and the OD600 of each culture was measured after 2, 329 3, 5, and 7 days of incubation. 330 331 MIC broth microdilution assays. MIC assays were performed in 96-well, round-bottom plates. 332 MABC strains were grown from frozen stock in growth medium, shaking, at 37°C, until the 333 cultures reached log-phase growth. The bacterial suspensions were then adjusted to 1 × 10 5 to 334 5 × 10 5 colony forming units per milliliter in assay medium, and 100 µl of this bacterial 335 suspension was added to each well, except for the no bacteria controls. Drug stock solutions 336 prepared from powder were diluted in assay medium to achieve the appropriate concentrations 337 in a final assay volume of 200 µl. Vaborbactam and relebactam were used at a final 338 concentration of 4 µg/ml (31, 39), a concentration readily achievable for both β-lactamase 339 inhibitors in human plasma (40, 41). Plates were sealed and incubated, undisturbed, at 30°C for 340 at least 72 hours or until there was sufficient growth in the drug-free bacterial growth control 341 wells (22). The MIC was defined as the lowest concentration of β-lactam that prevented growth 342 as observed by the naked eye. Two biological replicates of all MIC assays were performed. 343 MIC50 and MIC90 were defined as the MIC at which at least 50% and 90% of the clinical MABC 344 strains were inhibited, respectively. 
